$Phase 1 study of the anti-BCMA antibody-drug conjugate AMG 224 in patients with relapsed/refractory multiple myeloma$

Phase 1 study of the anti-BCMA antibody-drug conjugate AMG 224 in patients with relapsed/refractory multiple myeloma

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Leukemia 2021, Vol.35 (1), p.255-258
Hauptverfasser:	Lee, Hans C., Raje, Noopur S., Landgren, Ola, Upreti, Vijay V., Wang, Jin, Avilion, Ariel A., Hu, Xuguang, Rasmussen, Erik, Ngarmchamnanrith, Gataree, Fujii, Hisaki, Spencer, Andrew
Format:	Artikel
Sprache:	eng
Schlagworte:	45/23 631/67/1059/602 631/67/1990/804 Anemia Antibodies Antibody-drug conjugates Antigens Antineoplastic Agents, Immunological - administration & dosage Antineoplastic Agents, Immunological - adverse effects Antineoplastic Agents, Immunological - therapeutic use B-Cell Maturation Antigen - antagonists & inhibitors Cancer Research Care and treatment Critical Care Medicine Development and progression Drug dosages Drug Resistance, Neoplasm Gene expression Genetic aspects Health aspects Hematology Humans Immunoconjugates - administration & dosage Immunoconjugates - adverse effects Immunoconjugates - therapeutic use Intensive Internal Medicine Letter Medicine Medicine & Public Health Multiple myeloma Multiple Myeloma - diagnosis Multiple Myeloma - drug therapy Multiple Myeloma - etiology Multiple Myeloma - mortality Oncology Patient outcomes Patients Pharmacokinetics Recurrence Retreatment Thrombocytopenia Treatment Outcome Tumor antigens
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!